Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 278-285 |
| Seitenumfang | 8 |
| Fachzeitschrift | Pediatric pulmonology |
| Jahrgang | 46 |
| Ausgabenummer | 3 |
| Publikationsstatus | Veröffentlicht - März 2011 |
Abstract
Objective: Objective of this study is to assess and evaluate resource use in outpatient treatment in Germany and to compare it with remuneration. Methods: Outpatient treatment was evaluated in seven different centers for pediatric and adult CF patients. Data were recorded during one representative month in 2006. A micro-costing approachwas used to value resource use data. Results: For outpatient treatment mean costs (excluding drugs) of 488 per patient per quarter occurred. Correlation analyses identified significant cost drivers including age and co-morbidities (pancreatic insufficiency, hepatobiliary complications, lung function capacity, or bacterial lung colonization). Remuneration covered only 51% of the total costs (252 per patient/quarter). Conclusions: As the human resources available to these centers today are already below the requirements set by the European consensus for standards of CF care it will be important for a high level of patient care to reach a cost-covering remuneration scheme.
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Pädiatrie, Perinatalogie und Gesundheitsvorsorge bei Kindern
- Medizin (insg.)
- Lungen- und Bronchialmedizin
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Pediatric pulmonology, Jahrgang 46, Nr. 3, 03.2011, S. 278-285.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Resource usage in outpatient care and reimbursement for cystic fibrosis in Germany
AU - Eidt-Koch, Daniela
AU - Wagner, Thomas O.F.
AU - Mittendorf, Thomas
AU - Reimann, Andreas
AU - Von Der Schulenburg, J. Matthias
PY - 2011/3
Y1 - 2011/3
N2 - Objective: Objective of this study is to assess and evaluate resource use in outpatient treatment in Germany and to compare it with remuneration. Methods: Outpatient treatment was evaluated in seven different centers for pediatric and adult CF patients. Data were recorded during one representative month in 2006. A micro-costing approachwas used to value resource use data. Results: For outpatient treatment mean costs (excluding drugs) of 488 per patient per quarter occurred. Correlation analyses identified significant cost drivers including age and co-morbidities (pancreatic insufficiency, hepatobiliary complications, lung function capacity, or bacterial lung colonization). Remuneration covered only 51% of the total costs (252 per patient/quarter). Conclusions: As the human resources available to these centers today are already below the requirements set by the European consensus for standards of CF care it will be important for a high level of patient care to reach a cost-covering remuneration scheme.
AB - Objective: Objective of this study is to assess and evaluate resource use in outpatient treatment in Germany and to compare it with remuneration. Methods: Outpatient treatment was evaluated in seven different centers for pediatric and adult CF patients. Data were recorded during one representative month in 2006. A micro-costing approachwas used to value resource use data. Results: For outpatient treatment mean costs (excluding drugs) of 488 per patient per quarter occurred. Correlation analyses identified significant cost drivers including age and co-morbidities (pancreatic insufficiency, hepatobiliary complications, lung function capacity, or bacterial lung colonization). Remuneration covered only 51% of the total costs (252 per patient/quarter). Conclusions: As the human resources available to these centers today are already below the requirements set by the European consensus for standards of CF care it will be important for a high level of patient care to reach a cost-covering remuneration scheme.
KW - Cost analysis
KW - Cystic fibrosis
KW - Germany
KW - Reimbursement
UR - http://www.scopus.com/inward/record.url?scp=79951801790&partnerID=8YFLogxK
U2 - 10.1002/ppul.21364
DO - 10.1002/ppul.21364
M3 - Article
C2 - 24081887
AN - SCOPUS:79951801790
VL - 46
SP - 278
EP - 285
JO - Pediatric pulmonology
JF - Pediatric pulmonology
SN - 8755-6863
IS - 3
ER -